Biomark Diagnostics Inc
20B
Company Profile
Business description
Biomark Diagnostics Inc is developing its early-stage cancer diagnostic technology platform. It is cancer diagnostics technology platform leverages "Omics" and machine learning with a focus on how to detect and treat cancers. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Contact
10451 Shellbridge Way
Suite 145
RichmondBCV6X 2W8
CANSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,417.60 | 19.80 | -0.21% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,830.08 | 162.05 | 0.63% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,862.52 | 1,255.81 | 1.91% |
| NZX 50 Index | 13,844.17 | 20.04 | 0.14% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,228.60 | 21.00 | -0.23% |
| SSE Composite Index | 3,947.91 | 7.87 | 0.20% |